Injected BMCs expressed similar levels of MHC II, CD11c and CD11b 7 days after peritumoral injections as they did before injections, with low or undetectable IRF8 and CD103 expression (Additional file 1: Figure S3), suggesting that the lipophilic dye identified BMCs after tumor administration and that the TME did not affect expression of these molecules. The gene discussed is ITGAX; the disease is neoplasm.